Already approved by regulatory authorities, a biosimilar drug shares structure, biological activity, safety, and efficacy for the treatment of various diseases.

It contains a version of the active ingredient of the reference product, an equivalence established through a rigorous analytical comparability process, and can be available at lower costs than the original biologic.

The BioCubaFarma group, a mega-company that produces medicines, equipment, and high-tech services aimed at improving human health in Cuba, offers several biosimilars or generic products, such as EPOCIM, for treating chronic kidney failure, and Leukocim, for cancer.

The list includes Heberon Alfa R (Interferon alpha 2B) and PEG-Heberon, with anti-infective and cancer-fighting properties; human albumin, indicated for hypoproteinemia and nephrotic syndrome; and Enoxaparin sodium, an anticoagulant.

For the business group, the primary objective of this strategy is to facilitate the entry of new products into the National Health System, as well as to increase the institution’s portfolio of exportable products.

It also aims to complement its development line and introduce several other products not currently used in Cuba, among other purposes.

Specialists from BioCubaFarma presented this strategy at President Miguel Diaz-Canel’s regular meeting with scientists to discuss the country’s main health issues.

abo/arm/mem/alb